报价延迟最少15分钟:2025/09/03 19:25 EDT
盘后时段
|
||||
|
5.67 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.4
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.86/-1.16
|
|
企业价值
194.54M
|
| 资产负债 |
|
每股账面净值
-0.25
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/03 19:25 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. |
